Table 1.
Multidrug resistance (MDR) phenotype and frequencies1.
| Ceftiofur-resistant E. coli (n=649 isolates) | ||
|---|---|---|
| MDR Phenotype2 | Positive isolates | Frequency |
| AmpCefChlKanStrSulTetTri | 267 | 41.1% |
| AmcAmpCefChlKanStrSulTetTri | 101 | 15.6% |
| AmpCefChlCipKanStrSulTetTri | 85 | 13.1% |
| AmpCefKanStrSulTetTri | 73 | 11.2% |
| AmpCefCipKanSulTetTri | 46 | 7.1% |
| AmpCefCipKanStrSulTetTri | 33 | 5.1% |
| AmcAmpCefChlCipKanStrSulTetTri | 27 | 4.2% |
| AmcAmpCefChlKanStrSulTet | 11 | 1.7% |
| AmpCefStrSulTetTri | 6 | 0.9% |
| Florfenicol-resistant E. coli (n=1,256 isolates) | ||
| MDR Phenotype | Positive isolates | Frequency |
| AmpChlStrSulTet | 314 | 25.0% |
| AmpCefChlKanStrSulTetTri | 300 | 23.9% |
| AmpCefChlCipKanStrSulTetTri | 87 | 6.9% |
| AmpChlStrSulTetTri | 75 | 6.0% |
| AmpChlKanStrSulTet | 75 | 6.0% |
| AmpChlKanStrSulTetTri | 71 | 5.7% |
| AmcAmpCefChlKanStrSulTetTri | 52 | 4.1% |
| ChlKanStrSulTet | 50 | 4.0% |
| ChlKanStrSulTetTri | 41 | 3.3% |
| AmcAmpChlKanStrSulTetTri | 27 | 2.1% |
| AmpCefChlKanStrSulTet | 25 | 2.0% |
| AmpChlStrSul | 24 | 1.9% |
| ChlStrSulTetTri | 21 | 1.7% |
| ChlStrSulTet | 14 | 1.1% |
| AmpChlCipKanStrSulTetTri | 14 | 1.1% |
| AmcAmpChlStrSulTetTri | 14 | 1.1% |
| AmpCefChlStrSulTetTri | 13 | 1.0% |
| AmcAmpChlCipKanStrSulTetTri | 12 | 1.0% |
| AmcAmpCefChlCipKanStrSulTetTri | 8 | 0.6% |
| AmpCefChlStrSulTet | 5 | 0.4% |
| AmpChlSulTetTri | 4 | 0.3% |
| AmpChlKanSulTetTri | 4 | 0.3% |
| AmpChlSulTet | 3 | 0.2% |
| AmcAmpCefChlKanStrSulTet | 3 | 0.2% |
1
Phenotypes occurring with a frequency <2 were not included here.
2
AMP (ampicillin; 32 μg/mL); AMC (amoxicillin/clavulanic acid; 32/16 μg/mL); CEF (ceftiofur; 8 μg/mL); CHL (chloramphenicol; 34 μg/mL); TET (tetracycline; 16 μg/mL); CIP (ciprofloxacin; 4 μg/mL); STR (streptomycin; 16 μg/mL); KAN (kanamycin; 64 μg/mL); SUL (sulfamethoxazole; 512 μg/mL); TRI (trimethoprim; 8 μg/mL)